+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Completed

Phase 2
Age: 18Years +
All Genders
ID00000848

The Antiviral Effect of Switching From Hard Capsule Saquinavir SQVhc to the Soft Gelatin Capsule of Saquinavir SQVsc Versus Switching to Indinavir IDV After 1 Year of Saquinavir Use

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04

144

Participants Needed

16

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following prolonged use of the original hard capsule formulation of saquinavir results in an acute decrease in plasma HIV RNA. Resistance to anti-HIV agents occurs with increasing duration of use. In vitro studies have shown that cross-resistance occurs among protease inhibitors, although no clinical trials have been conducted to examine antiretroviral activity with sequential use of protease inhibitors or to determine whether saquinavir resistance can be overcome with higher concentrations of the drug.

CONDITIONS

Brief Title

The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here